{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218175","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2026-05-12T11:20:21+00:00","discovered_at":"2026-05-12T11:25:00.314908+00:00","generated_at":"2026-05-12T11:25:20.035023+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed","bullets":["Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.","Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).","Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.","Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.","Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218175","json":"https://secwatch.observer/filing/0001193125-26-218175.json","markdown":"https://secwatch.observer/filing/0001193125-26-218175.md","text":"https://secwatch.observer/filing/0001193125-26-218175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/d854692d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:25:20.035023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c97e4aa29cc2d28cbe1710448fb054e9a5baf6a","claim":"ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter of 2026.","evidence_excerpt":"today announced financial results for the first quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6cdf13f0bf42b8357ff3c4e4b6e25916275c0559","claim":"ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Achieve Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9926643b9ed8484bb8a5d7cd287db64e160364e8","claim":"ACHIEVE LIFE SCIENCES, INC. reported the three months ended March 31, 2026 results: net income $10.2 million.","evidence_excerpt":"Total operating expenses and net loss for the three months ended March 31, 2026 were $10.5 million and $10.2 million, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"$10.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"21f32ce963","claim":"Thomas King resigned as Chairman of the Board and Member at ACHIEVE LIFE SCIENCES, INC..","evidence_excerpt":"Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board and Member"}],"fact_type":"executive_change"},{"claim_id":"72ce4ea238","claim":"Jaime Xinos departed as Chief Commercial Officer at ACHIEVE LIFE SCIENCES, INC..","evidence_excerpt":"Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"a77a72bb28","claim":"Lucian Iancovici was appointed as Chair of the Board at ACHIEVE LIFE SCIENCES, INC..","evidence_excerpt":"Lucian Iancovici, MD, was appointed as Chair of the Board, effective as of June 8, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"df60bd3564","claim":"Christopher Martin was appointed as Director at ACHIEVE LIFE SCIENCES, INC..","evidence_excerpt":"appointed Christopher Martin to serve as a director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}